Non-Small-Cell Lung Cancer Clinical Trial
— CheckMate 568Official title:
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
Verified date | March 2023 |
Source | Bristol-Myers Squibb |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of part 1 of this study is to determine the objective response rate (ORR) in stage IV NSCLC subjects treated with nivolumab in combination with ipilimumab as first line therapy. The purpose of part 2 of this study is to determine the safety and tolerability of nivolumab and ipilimumab combined with a short course of chemotherapy in first line stage IV NSCLC.
Status | Completed |
Enrollment | 324 |
Est. completion date | March 7, 2022 |
Est. primary completion date | June 22, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men and Women = 18 years of age - Diagnosed with stage IV Non-Small Cell Lung Cancer - Diagnosed with recurrent stage IIIB non-small cell lung cancer and failed previous concurrent chemoradiation with no further curative options. Exclusion Criteria: - Subjects with untreated CNS metastases are excluded. - Subjects with carcinomatous meningitis - Subjects with an active, known or suspected autoimmune disease. - Subjects with a condition requiring systemic treatment with either corticosteroids ( > 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first treatment. - Women who are pregnant, plan to become pregnant, and/or breastfeed during the study. Other protocol defined inclusion/exclusion criteria apply |
Country | Name | City | State |
---|---|---|---|
Canada | Local Institution - 0022 | Kingston | Ontario |
Canada | Local Institution - 0023 | Sault Ste Marie | Ontario |
Canada | Csss De St-Jerome | St. Jerome | Quebec |
United States | Local Institution - 0036 | Albuquerque | New Mexico |
United States | Lovelace Cancer Care | Albuquerque | New Mexico |
United States | New Mexico Cancer Care Alliance | Albuquerque | New Mexico |
United States | New Mexico Cancer Care Center | Albuquerque | New Mexico |
United States | The Cancer Center at Presbyterian | Albuquerque | New Mexico |
United States | Winship Cancer Institute. | Atlanta | Georgia |
United States | Johns Hopkins Cancer Center | Baltimore | Maryland |
United States | Local Institution - 0029 | Boston | Massachusetts |
United States | Local Institution - 0030 | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Charleston Hematology Oncology Associates, Pa | Charleston | South Carolina |
United States | The Ohio State University | Columbus | Ohio |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Duke University | Durham | North Carolina |
United States | Hackensack University Medical Center | Hackensack | New Jersey |
United States | Local Institution - 0015 | Lincoln | Nebraska |
United States | University Of Louisville Medical Center, Inc., Dba | Louisville | Kentucky |
United States | Local Institution - 0010 | Mineola | New York |
United States | Tennessee Oncology, PLLC - SCRI - PPDS | Nashville | Tennessee |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Memorial Sloan Kettering Nassau | New York | New York |
United States | Fox Chase Cancer Center | Philadelphia | Pennsylvania |
United States | Local Institution - 0006 | Pittsburgh | Pennsylvania |
United States | Cancer Center Of Central Connecticut | Plainville | Connecticut |
United States | Sharp Memorial Hospital | San Diego | California |
United States | Summit Cancer Care | Savannah | Georgia |
United States | Cleveland Clinic Florida | Weston | Florida |
United States | Cancer Center Of Kansas | Wichita | Kansas |
United States | Novant Health Oncology Specialists | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Bristol-Myers Squibb |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1 | Objective response rate (ORR) in PD-L1 positive (PD-L1 =1%) and PD-L1 negative (PD-L1 <1%) participants was defined as the percentage of treated participants with confirmed complete response (CR) or partial response (PR) per RECIST 1.1 based on Blinded Independent Central Review (BICR) assessment. | From first dose to database lock (Up to 18 months) | |
Primary | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 2 | Dose limiting toxicities (DLTs) were defined as any of the items listed below. Any Grade 2 drug-related uveitis or eye pain that does not respond to topical therapy and does not improve to Grade 1 severity within the re-treatment period OR requires systemic treatment. Any Grade 2 drug-related pneumonitis or interstitial lung disease that does not resolve to dose delay and systemic steroids in 14 days. Any Grade 3 non-skin drug-related adverse event with the exception of laboratory abnormalities that cannot be alleviated or controlled by appropriate care within 14 days. Any Grade 4 drug-related adverse event including laboratory abnormalities except Grade 4 leukopenia or neutropenia lasting < 14 days and asymptomatic amylase/lipase elevation. Drug-related hepatic function laboratory abnormalities. |
9 weeks after first dose | |
Primary | Number of Participants With Adverse Events (AEs) - Part 2 | Number of participants with adverse events (AEs) including serious adverse events (SAEs) and deaths graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Ipilimumab combined with chemotherapy. | Deaths are from first dose to database lock (Up to 24 months). AEs and SAEs are from first dose to 30 days post last dose | |
Primary | Number of Participants With Laboratory Abnormalities in Hepatic Tests - Part 2 | Number of participant with specific liver laboratory abnormalities graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Ipilimumab combined with chemotherapy. | From first dose to 30 days post last dose | |
Primary | Number of Participants With Laboratory Abnormalities in Thyroid Tests - Part 2 | Number of participants with specific thyroid laboratory abnormalities graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Ipilimumab combined with chemotherapy. | From first dose to 30 days post last dose | |
Secondary | Overall Survival (OS) - Part 1 | Overall survival (OS) was defined as the time from date of first treatment to the date of death due to any cause. A participant who has not died will be censored at the last known date alive. | From the date of first treatment to the date of death due to any cause (Up to approximately 72 months) | |
Secondary | Overall Survival (OS) - Part 2 | Overall survival (OS) was defined as the time from date of first treatment to the date of death due to any cause. A participant who has not died will be censored at the last known date alive. | From the date of first treatment to the date of death due to any cause (Up to approximately 59 months) | |
Secondary | Progression Free Survival (PFS) - Part 1 | Progression Free Survival (PFS) was defined as the time between the date of first dose and the first date of documented progression, as determined by blinded independent central review (BICR), or death due to any cause, whichever occurred first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. | From first dose to the first date of documented progression, or death due to any cause, whichever occurred first (Up to approximately 72 months) | |
Secondary | Progression Free Survival (PFS) - Part 2 | Progression Free Survival (PFS) was defined as the time between the date of first dose and the first date of documented progression, as determined by investigator (per RECIST 1.1), or death due to any cause, whichever occurred first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. | From first dose to the first date of documented progression, or death due to any cause, whichever occurred first (Up to approximately 59 months) | |
Secondary | Objective Response Rate (ORR) - Part 1 | Objective response rate (ORR) was defined as the percentage of treated participants with confirmed complete response (CR) or partial response (PR) per RECIST 1.1 based on Blinded Independent Central Review (BICR) assessment. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From first dose up to approximately 72 months | |
Secondary | Objective Response Rate (ORR) - Part 2 | Objective response rate (ORR) was defined as the percentage of treated participants with confirmed complete response (CR) or partial response (PR) per RECIST 1.1 based on investigator assessment. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
From first dose up to approximately 59 months | |
Secondary | Overall Survival (OS) by PD-L1 Expression Levels - Part 1 | Overall survival (OS) by PD-L1 expression levels was defined as the time from date of first treatment to the date of death due to any cause. A participant who has not died will be censored at the last known date alive. PD-L1 =1% = PD-L1 positive (membranous staining in = 1% tumor cells) PD-L1 <1% = PD-L1 negative (membranous staining in <1% tumor cells) |
From the date of first treatment to the date of death due to any cause (Up to approximately 72 months) | |
Secondary | Progression Free Survival (PFS) by PD-L1 Expression Levels - Part 1 | Progression Free Survival (PFS) by PD-L1 expression levels was defined as the time between the date of first dose and the first date of documented progression, as determined by blinded independent central review (BICR), or death due to any cause, whichever occurred first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD-L1 =1% = PD-L1 positive (membranous staining in = 1% tumor cells) PD-L1 <1% = PD-L1 negative (membranous staining in <1% tumor cells) |
From first dose to the first date of documented progression, or death due to any cause, whichever occurred first (Up to approximately 72 months) | |
Secondary | Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1 | Objective response rate (ORR) by PD-L1 expression levels was defined as the percentage of treated participants with confirmed complete response (CR) or partial response (PR) per RECIST 1.1 based on Blinded Independent Central Review (BICR) assessment. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD-L1 =1% = PD-L1 positive (membranous staining in = 1% tumor cells) PD-L1 <1% = PD-L1 negative (membranous staining in <1% tumor cells) |
From first dose up to approximately 72 months | |
Secondary | Overall Survival (OS) by Tumor Mutation Burden (TMB) Levels - Part 1 | Overall survival (OS) by tumor mutational burden (TMB) using DNA derived from tumor specimens was defined as the time from date of first treatment to the date of death due to any cause. A participant who has not died will be censored at the last known date alive. High TMB = = 10 mutations per megabase Low TMB = < 10 mutations per megabase |
From the date of first treatment to the date of death due to any cause (Up to approximately 72 months) | |
Secondary | Progression Free Survival (PFS) by Tumor Mutation Burden (TMB) Levels - Part 1 | Progression Free Survival (PFS) by tumor mutational burden (TMB) using DNA derived from tumor specimens was defined as the time between the date of first dose and the first date of documented progression, as determined by blinded independent central review (BICR), or death due to any cause, whichever occurred first. Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. High TMB = = 10 mutations per megabase Low TMB = < 10 mutations per megabase |
From first dose to the first date of documented progression, or death due to any cause, whichever occurred first (Up to approximately 72 months) | |
Secondary | Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1 | Objective response rate (ORR) by tumor mutational burden (TMB) using DNA derived from tumor specimens was defined as the percentage of treated participants with confirmed complete response (CR) or partial response (PR) per RECIST 1.1 based on Blinded Independent Central Review (BICR) assessment. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. High TMB = = 10 mutations per megabase Low TMB = < 10 mutations per megabase |
From first dose up to approximately 72 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Not yet recruiting |
NCT02938546 -
18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
|
Phase 3 |